158 related articles for article (PubMed ID: 17315909)
21. The prognostic significance of COX-2 and survivin expression in ovarian cancer.
Athanassiadou P; Grapsa D; Athanassiades P; Gonidi M; Athanassiadou AM; Tsipis A; Patsouris E
Pathol Res Pract; 2008; 204(4):241-9. PubMed ID: 18171606
[TBL] [Abstract][Full Text] [Related]
22. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
[TBL] [Abstract][Full Text] [Related]
23. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract][Full Text] [Related]
24. [Identification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?].
Petri AL; Høgdall E; Engelholm SA; Christensen IJ; Kjaer SK; Høgdall CK
Ugeskr Laeger; 2007 Aug; 169(33):2614-9. PubMed ID: 17725906
[TBL] [Abstract][Full Text] [Related]
25. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
Zheng Y; Katsaros D; Shan SJ; de la Longrais IR; Porpiglia M; Scorilas A; Kim NW; Wolfert RL; Simon I; Li L; Feng Z; Diamandis EP
Clin Cancer Res; 2007 Dec; 13(23):6984-92. PubMed ID: 18056174
[TBL] [Abstract][Full Text] [Related]
26. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
Wang Q; Zhang W; Li DR; Li L
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1012-6. PubMed ID: 18754431
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumor antibodies in ovarian cancer.
Luborsky JL; Barua A; Shatavi SV; Kebede T; Abramowicz J; Rotmensch J
Am J Reprod Immunol; 2005 Aug; 54(2):55-62. PubMed ID: 16105096
[TBL] [Abstract][Full Text] [Related]
28. Early diagnosis and predictors of malignancy of adnexal masses.
Murta EF; Nomelini RS
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):14-9. PubMed ID: 16493254
[TBL] [Abstract][Full Text] [Related]
29. Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT).
Sodek KL; Evangelou AI; Ignatchenko A; Agochiya M; Brown TJ; Ringuette MJ; Jurisica I; Kislinger T
Mol Biosyst; 2008 Jul; 4(7):762-73. PubMed ID: 18563251
[TBL] [Abstract][Full Text] [Related]
30. Proteomics and biomarkers for ovarian cancer diagnosis.
Zhang B; Barekati Z; Kohler C; Radpour R; Asadollahi R; Holzgreve W; Zhong XY
Ann Clin Lab Sci; 2010; 40(3):218-25. PubMed ID: 20689132
[TBL] [Abstract][Full Text] [Related]
31. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
Jurisicova A; Jurisica I; Kislinger T
Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
[TBL] [Abstract][Full Text] [Related]
32. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
33. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer.
Ye B; Gagnon A; Mok SC
Expert Rev Proteomics; 2007 Feb; 4(1):121-31. PubMed ID: 17288520
[TBL] [Abstract][Full Text] [Related]
34. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
35. Artificial neural networks and decision tree model analysis of liver cancer proteomes.
Luk JM; Lam BY; Lee NP; Ho DW; Sham PC; Chen L; Peng J; Leng X; Day PJ; Fan ST
Biochem Biophys Res Commun; 2007 Sep; 361(1):68-73. PubMed ID: 17644064
[TBL] [Abstract][Full Text] [Related]
36. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
[TBL] [Abstract][Full Text] [Related]
38. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
39. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
40. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
